Straits Times Index
3,326.04 -4.05 (-0.12%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,727.37 -303.26 (-0.45%) CMC Crypto 200
1,463.73 -20.96 (-1.41%)
Sedana Medical AB (publ) (SEDANA.ST)
| Previous close | 22.45 |
| Open | 23.40 |
| Bid | 22.95 x 0 |
| Ask | 22.95 x 0 |
| Day's range | 22.30 - 23.45 |
| 52-week range | 13.88 - 34.50 |
| Volume | |
| Avg. volume | 261,431 |
| Market cap | 2.28B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.24 |
| Earnings date | 23 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.00 |
PR NewswireSedana Medical completes patient recruitment for its clinical program in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
PR NewswireSedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
